PuSH - Publikationsserver des Helmholtz Zentrums München

Salminen, A.V. ; Schandra, N. ; Schormair, B. ; Oexle, K. ; Winkelmann, J.

Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome.

J. Clin. Sleep Med. 16, 1815-1817 (2020)
Verlagsversion DOI PMC
Free by publisher
: Postprint online verfügbar 10/2021
None: Recent developments in the genetics of restless legs syndrome (RLS) revealed associations of disease risk with genetic loci containing the genes coding cereblon, the protein bound by thalidomide, and its endogenous substrate MEIS2, whose degradation is inhibited by the thalidomide-cereblon interaction. Therefore it was hypothesized that thalidomide may be a potential treatment option for RLS. Here we report on the therapeutic effect of thalidomide in a patient with otherwise treatment-resistant RLS who received 100 mg thalidomide off-label for 3 weeks. The female patient, severely affected by RLS before treatment, experienced significant amelioration of the symptoms, increased self-reported sleep quality, and better daytime functioning during thalidomide treatment. This therapeutic success warrants larger studies investigating the efficacy of drugs of the thalidomide class in RLS.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Case Report ; Restless Legs Syndrome ; Thalidomide ; Treatment; Validation; Daytime; Scale
ISSN (print) / ISBN 1550-9389
e-ISSN 1550-9397
Zeitschrift Journal of clinical sleep medicine
Quellenangaben Band: 16, Heft: 10, Seiten: 1815-1817 Artikelnummer: , Supplement: ,
Verlag American Academy of Sleep Medicine and the Sleep Research Society
Verlagsort Darien, IL
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Neurogenomics (ING)